Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Longjiang She"'
Autor:
Siqi Tang, Zhenyu Wu, Lusi Chen, Longjiang She, Weihan Zuo, Weijun Luo, Yang Zhang, Shaoqiang Liang, Guichao Liu, Biyi He, Jinfeng He, Ning Zhang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundNasopharyngeal carcinoma (NPC) is prevalent in Southern China. The expression profile and functions of kinesin family member 18B (KIF18B) remain unclear in NPC.MethodsBulk and single-cell transcriptome data for NPC were downloaded. KIF18B e
Externí odkaz:
https://doaj.org/article/abad0182abc2401a8b0a14b1110e5d09
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metrono
Externí odkaz:
https://doaj.org/article/930dee17328f4e3a815ecad9de4b4859
Autor:
Huabin Hu, Longjiang She, Mengting Liao, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, David P. Carbone, Jin Huang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The CheckMate 227 trial has indicated that nivolumab plus ipilimumab compared with chemotherapy significantly increases long-term survival in the first-line setting of advanced non-small-cell lung cancer (NSCLC).Methods: A Markov model wa
Externí odkaz:
https://doaj.org/article/45321d69ce954fd8b668e7329a51f6b6
Autor:
Jiaqi Han MD, Desheng Xiao PhD, Chongqing Tan PhD, Xiaohui Zeng MD, Huabin Hu MD, Shan Zeng PhD, MD, Qin Jiang MD, Longjiang She MD, Linli Yao MD, Li Li MD, Lanhua Tang PhD, Jian Ma PhD, MD, Jin Huang PhD, MD, Liangfang Shen PhD, MD
Publikováno v:
Cancer Control, Vol 27 (2020)
Background: The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) by 38.3 months after treatment with i
Externí odkaz:
https://doaj.org/article/86f087976bbc451ea2f0a58444abe768
Publikováno v:
Journal of Low Frequency Noise, Vibration and Active Control, Vol 43 (2024)
In order to compare the differences in vibration before and after wheel re-profiling and assess the vibration impact of train under full-load and empty-load condition, the field vibration measurement was conducted on an underground metro track compon
Externí odkaz:
https://doaj.org/article/951be84bc38b4921a18285bab0b7f372
Publikováno v:
Oral oncology. 129
Recently, updated data from KEYNOTE-048 revealed that pembrolizumab with or without chemotherapy could improve progression-free survival (PFS)2 compared with cetuximab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
Autor:
Yin Shi, Linli Yao, Dong Ding, Jin Huang, Shan Zeng, Liangfang Shen, Longjiang She, Huabin Hu, Youwen Zhu
Publikováno v:
Oncologist
Background The data from the phase III clinical trial KEYNOTE-426 indicated that pembrolizumab plus axitinib compared with sunitinib could generate clinical benefits in patients with previously untreated advanced renal cell carcinoma (RCC). Given the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4271ea2f9f3f5816a6162001e5e57505
https://europepmc.org/articles/PMC7873332/
https://europepmc.org/articles/PMC7873332/
Autor:
Yin Shi, Huabin Hu, Youwen Zhu, Dong Ding, Mengting Liao, Jin Huang, Linli Yao, Longjiang She, Shan Zeng
Publikováno v:
Advances in therapy. 37(5)
The purpose of this study was to estimate the cost-effectiveness of atezolizumab plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the United States (US) payers’ perspective in the first-line treatme
Autor:
Yin Shi, Youwen Zhu, Dong Ding, Shan Zeng, David P. Carbone, Longjiang She, Linli Yao, Liangfang Shen, Xuefeng Xia, Mengting Liao, Huabin Hu, Jin Huang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 138
Objective The purpose of this study was to estimate the cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1
Autor:
Dong Ding, Longjiang She, Jiaqi Han, Huabin Hu, Qin Jiang, Linli Yao, Mengting Liao, Jin Huang
Publikováno v:
Journal of medical economics. 22(6)
Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and t...